Member Info for EmeraldCarrots

Investors are. It's staring the market in the face. A fully grown African bull Elephant in the room and you have not noticed!!!!!!!!!!!

Yes, it's on that "Indeed" site. Along with another 8 vacancies mostly to do with Molecular.

Either have, or are expecting a lot of DNA analysis work. How strange? LOL!

Astrazeneca are now using liquid biopsies to monitor patient reponse during cancer drug trials. Angle Plc's "dual analysis" is the "Rolls Royce" of liquid biopsy analysis. Simple as that.

75p a share?

All IMHO.

Of cancer liquid biopsy DNA analysis, which is of course Angle's "dual analysis"? That is CtDna analysis (analysing fragments of Dna in the blood) and CTC (circulating tumour cell) analysis combined, using Angles Parsortix method which catches live and intact CTC's for the analysis. Note Angle already work closely with Astrazeneca.

All IMHO.

1. Astrazeneca are now using CtDna analysis to guide treatment options during their drug trials. Angle's "dual analysis” is better. It is the "normal" CtDna analysis plus circulating tumour cell (CTC) analysis combined giving far better results and the complete picture. This could be massive for Angle. Pharma Co’s should SAVE MONEY and patients lives using analysis to see if the treatments are working almost live rather than weeks/months later. Treatments can be stopped if not working and alternatives applied.

2. The Illumina connection.

Joint promotion of "dual analysis" with Illumina. No word on this yet. However, from Illumina's point of view why not? They have already created an assay panel working with Angle specifically for dual analysis of lung cancer. Illumina's share price has been suffering of late. What if they go for this bigtime? Astrazeneca are doing a trial now that uses CtDna to test what drug to use. Dual analysis goes one step further. CtDna analysis and CTC Dna analysis of the same blood sample roughly doubling the number of cancer biomarkers found.

If Illumina don't go for it bigtime some other Company likely will in any case.

3. Results any day.

All IMHO.

Up again.

To promote their so called "dual analysis" with Illumina. No word on this yet. However, from Illumina's point of view why not? They have already created an assay panel working with Angle specifically for dual analysis of lung cancer. Illumina's share price has been suffering of late. What if they go for this bigtime? Astrazeneca are doing a trial now than uses CtDna to test what drug to use. Dual analysis goes one step further. CtDna analysis and CTC Dna analysis of the same blood sample roughly doubling the number of cancer biomarkers found.

If Illumina don't go for it bigtime some other Company likely will in any case.

All IMHO.

Cancerous cells. Makes one wonder if they will be able to do something with them or see what needs to be changed. Food for thought. Angle's Parsortix can catch live, intact circulating cancer cells for study and analysis.

Astra are now using CtDna analysis to guide treatment. The market sees that, and knows (at least some do), that Angle's "Dual Analysis" is one step beyond CtDna analysis on it's own. It is CtDna analysis combined with CTC analysis and gives better results. So will dual analysis be next. The market clearly suspects it will be! This is big news.

Https://www.astrazeneca.com/media-centre/press-releases/2025/astrazenecas-record-seventh-year-of-plenary-data-at-asco-furthers-ambition-to-redefine-breast-cancer-care-and-transform-outcomes-in-gastric-cancer.html

Like me.

C R A Z Y !

15.62% up

Too by the looks........

Would be good. 9.25p to 160p. LOL! Knock £1 off and it might happen IMHO.

Up 15.62%.

To 9.5p. Appears like a sell though of course.

LSBM.

You are right. Their website says May for the preliminary results. Last year it was 5th June.

This or nect week then. I shall buy some more tissues just in case. LOL!

Angle getting a bid. I'm lost for words.

LSBM.

Sp slightly unusual IMHO for a few days but results due early June.

I know Angle want to jointly promote dual analysis with Illumina, but will Illumina play ball?

I don't see why not. Dual analysis could be standard in a few years.

The CtDda only analysis Co's could lose out bigtime.

I honestly think they will.

Illumina are on the ball; the rest are asleep.......... or planning a bid for Angle Plc.

All IMHO.

"DESTINY-Breast09 Phase III trial of Enhertu (trastuzumab deruxtecan) in combination with pertuzumab in the 1st-line treatment of patients with HER2-positive metastatic breast cancer (Oral Abstract #LBA1008).".

Https://www.astrazeneca.com/media-centre/press-releases/2025/astrazenecas-record-seventh-year-of-plenary-data-at-asco-furthers-ambition-to-redefine-breast-cancer-care-and-transform-outcomes-in-gastric-cancer.html